Aussie direct-to-patient model lifts off

 Posted 28 March 2025 AM

Proteomics International Laboratories has launched a digital direct-to-patient campaign aimed at the 600,000 Australians with diabetes at risk of developing kidney disease, to commercialise its diagnostic test, PromarkerD.

Using the RoseRx doctor-developed patient engagement program, an extensive digital direct-to-patient campaign will raise awareness among eligible patients and provide them with clinical follow-up care options in Western Australia and the Northern Territory before expanding nationally in coming months.

To see the whole article, please login